Pancreatic adenocarcinoma:Beyond first line,where are we?  

作　　者：Sara Cherri Silvia Noventa Alberto Zaniboni 

机构地区：[1]Department of Oncology,Fondazione Poliambulanza,Brescia 25124,Italy

出　　处：《World Journal of Gastroenterology》2021年第17期1847-1863,共17页世界胃肠病学杂志（英文版）

摘　　要：Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providing only a slight advantage in terms of survival.The molecular and cellular characteristics of pancreatic cancer cells,as well as the cells that characterize the pancreatic tumour microenvironment,are the basis of the mechanisms of resistance to treatment.After progression during first-line treatment,few patients are eligible for secondline treatment due to the loss of performance status.To date,a clear survival advantage has not yet been demonstrated for second-line chemotherapy.Precision medicine could be the key to increasing responses to cancer treatment and finally impacting survival in this difficult-to-treat disease.In this review,we analyze current recommendations in the second-line setting and potential future prospects.

关 键 词：Pancreatic adenocarcinoma SECOND-LINE CHEMOTHERAPY Targeted therapy IMMUNOTHERAPY 

分 类 号：R735.9[医药卫生—肿瘤]